Weaning off tirzepatide requires the same patience and monitoring as the initial dose escalation phase
Noom first launched its GLP-1 Companion in November 2023 and has continued to invest heavily in the program since launch, adding features like Muscle Defense, AI food logging, medication tracking and side effect support, AI-powered body composition scans, glucose curve forecasting, stress-relief activities, and gamification of healthy behaviors like achieving step goals and eating healthy snacks
Tirzepatide goes further
Following a low-fat diet may help reduce or minimize these side effects
N Engl J Med 389(6):514526 Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S et al (2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Preparing your injection space can help reduce anxiety